MedTrace Logo

Methylphenidate for Cocaine Dependence

NCT03090269 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-07-20

No results posted yet for this study

Summary

This phase II pilot study aims at evaluating the benefits and the risks of methylphenidate (Concerta®) for the treatment of cocaine/crack dependence in terms of cocaine/crack use reduction and adverse events.

Conditions

  • Substance-Related Disorders

Interventions

DRUG

Methylphenidate Pill

3-month follow-up to study the effective dose as a treatment for cocaine dependence in toxicity and reduction in cocaine use

Sponsors & Collaborators

  • Hopital Paul Brousse

    collaborator OTHER

  • ANRS, Emerging Infectious Diseases

    lead OTHER_GOV

Principal Investigators

  • Amine Benyamina, Pr · Hôpital Paul Brousse APHP - France

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2018-12-31
Completion
2019-03-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03090269 on ClinicalTrials.gov